We are live on ! Find out more
LCM

Lynx1 Capital Management Portfolio holdings

AUM $633M
1-Year Est. Return 173.22%
This Fund
S&P 500
This Quarter Est. Return
-17.18%
1 Year Est. Return
+173.22%
3 Year Est. Return
+779.42%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$267M
AUM Growth
-$15.5M
Cap. Flow
+$62M
Cap. Flow %
23.23%
Top 10 Hldgs %
95.76%
Holding
24
New
6
Increased
5
Reduced
2
Closed
6

Top Buys

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$28.3M
2
CGEM icon
Cullinan Oncology
CGEM
+$12.2M
3
ALLO icon
Allogene Therapeutics
ALLO
+$11.5M
4
DTIL icon
Precision BioSciences
DTIL
+$5.59M
5
UPB
Upstream Bio Inc
UPB
+$5.36M

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$10.2M
2
KOD icon
Kodiak Sciences
KOD
+$708K
3
PVLA
Palvella Therapeutics
PVLA
+$621K
4
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$206K
5
CCCC icon
C4 Therapeutics
CCCC
+$138K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
1
DELISTED
Merus
MRUS
$66.5M 24.92%
1,580,841
-213,025
-12% -$10.2M
STOK icon
2
Stoke Therapeutics
STOK
$1.82B
$57.2M 21.45%
5,187,191
– –
GHRS icon
3
GH Research
GHRS
$1.87B
$34M 12.75%
4,858,994
+663,100
+16% +$5.33M
CCCC icon
4
C4 Therapeutics
CCCC
$376M
$24.7M 9.25%
6,852,744
-27,783
-0.4% -$138K
ALLO icon
5
Allogene Therapeutics
ALLO
$601M
$23.2M 8.68%
10,874,723
+4,672,349
+75% +$11.5M
TCRX icon
6
TScan Therapeutics
TCRX
$51.9M
$16.3M 6.11%
5,357,347
+132,747
+3% +$602K
CGEM icon
7
Cullinan Oncology
CGEM
$1.05B
$15.3M 5.74%
1,257,795
+846,965
+206% +$12.2M
KROS icon
8
Keros Therapeutics
KROS
$199M
$8.61M 3.23%
+544,001
New +$28.3M
PASG icon
9
Passage Bio
PASG
$15.9M
$5.25M 1.97%
462,848
+41,500
+10% +$541K
ALLK
10
DELISTED
Allakos
ALLK
$4.39M 1.65%
+3,628,144
New +$3.81M
UPB
11
Upstream Bio Inc
UPB
$349M
$3.95M 1.48%
+240,042
New +$5.36M
DTIL icon
12
Precision BioSciences
DTIL
$188M
$2.92M 1.09%
+766,051
New +$5.59M
IBIO icon
13
iBio
IBIO
$71M
$2.11M 0.79%
862,279
– –
CRBU icon
14
Caribou Biosciences
CRBU
$156M
$1.08M 0.41%
680,189
– –
VOR icon
15
Vor Biopharma
VOR
$1.04B
$707K 0.27%
+31,861
New +$528K
CNTA
16
DELISTED
Centessa Pharmaceuticals
CNTA
$291K 0.11%
17,400
– –
NEUP
17
Neuphoria Therapeutics
NEUP
$19.7M
$157K 0.06%
45,806
– –
RPTX
18
DELISTED
Repare Therapeutics
RPTX
$104K 0.04%
+79,176
New +$236K
IPSC icon
19
Century Therapeutics
IPSC
$381M
– –
-19,028
Closed -$32.5K
KNSA icon
20
Kiniksa Pharmaceuticals
KNSA
$4.83B
– –
-8,231
Closed -$206K
KOD icon
21
Kodiak Sciences
KOD
$2.59B
– –
-271,177
Closed -$708K
TENX icon
22
Tenax Therapeutics
TENX
$385M
– –
-14,751
Closed -$51K
VYNE icon
23
VYNE Therapeutics
VYNE
$340K
– –
-16,194
Closed -$30.4K
PVLA
24
Palvella Therapeutics
PVLA
$1.98B
– –
-37,436
Closed -$621K

Similar funds

SWM
SilverOak Wealth Management Edina, Minnesota $632M AUM 18.6% 1-Year Est. Return
RFA
Rollins Financial Advisors New York City, New York $632M AUM 23.84% 1-Year Est. Return
WA
WFM Asia Road Town, Tortola, British Virgin Islands $632M AUM 14.51% 1-Year Est. Return
AMM
American Money Management Rancho Santa Fe, California $632M AUM 14.06% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
ACM
Arini Captial Management London, United Kingdom $634M AUM
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return

Lynx1 Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Lynx1 Capital Management held 24 positions worth $267M, down 5.5% from $282M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Lynx1 Capital Management deployed $62M of net new capital in Q4 2024, opening 6 new positions and adding to 5 existing holdings. Its largest new stake was Keros Therapeutics: 544,001 shares worth $8.61M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Merus, an estimated $10.2M trimmed.

  • Lynx1 Capital Management's largest Q4 2024 buy was Keros Therapeutics: 544,001 shares worth $8.61M.
  • Lynx1 Capital Management added most to Cullinan Oncology in Q4 2024, an estimated $12.2M increase.
  • Lynx1 Capital Management's biggest Q4 2024 reduction was Merus, cutting an estimated $10.2M.
  • Lynx1 Capital Management fully exited Kodiak Sciences in Q4 2024, selling an estimated $708K.
  • Lynx1 Capital Management's ten largest holdings make up 96% of its $267M portfolio in Q4 2024.
  • Lynx1 Capital Management opened 6 new positions and closed 6 in Q4 2024.
  • Lynx1 Capital Management's portfolio value fell 5.5% quarter-over-quarter to $267M.

Based on Lynx1 Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.